|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0014582,
umls-concept:C0020792,
umls-concept:C0178602,
umls-concept:C0205177,
umls-concept:C0205179,
umls-concept:C0246415,
umls-concept:C1274040,
umls-concept:C1516213,
umls-concept:C1522410,
umls-concept:C2603343
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2001-10-3
|
|
pubmed:abstractText |
To determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of docetaxel in combination with fixed doses of epirubicin.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BergaglioMM,
pubmed-author:CognettiFF,
pubmed-author:Del MastroLL,
pubmed-author:DonathRR,
pubmed-author:FrevolaLL,
pubmed-author:LionettoRR,
pubmed-author:LunardiGG,
pubmed-author:MichelottiAA,
pubmed-author:PapaldoPP,
pubmed-author:RossiLL,
pubmed-author:SguottiCC,
pubmed-author:VenturiniMM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1097-106
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11583191-Adult,
pubmed-meshheading:11583191-Aged,
pubmed-meshheading:11583191-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11583191-Breast Neoplasms,
pubmed-meshheading:11583191-Dose-Response Relationship, Drug,
pubmed-meshheading:11583191-Epirubicin,
pubmed-meshheading:11583191-Female,
pubmed-meshheading:11583191-Humans,
pubmed-meshheading:11583191-Maximum Tolerated Dose,
pubmed-meshheading:11583191-Middle Aged,
pubmed-meshheading:11583191-Neoplasm Metastasis,
pubmed-meshheading:11583191-Neoplasm Staging,
pubmed-meshheading:11583191-Paclitaxel,
pubmed-meshheading:11583191-Taxoids
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
|
|
pubmed:affiliation |
Division of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy. mventur@hp380.ist.unige.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Clinical Trial, Phase I
|
